phorbol-12-myristate has been researched along with Cancer of Prostate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kazanietz, MG; von Burstin, VA; Xiao, L | 1 |
| Carraway, RE; Dobner, PR; Hassan, S | 1 |
2 other study(ies) available for phorbol-12-myristate and Cancer of Prostate
| Article | Year |
|---|---|
Bryostatin 1 inhibits phorbol ester-induced apoptosis in prostate cancer cells by differentially modulating protein kinase C (PKC) delta translocation and preventing PKCdelta-mediated release of tumor necrosis factor-alpha.
Topics: Antineoplastic Agents; Apoptosis; Bryostatins; Humans; Isoenzymes; Lactones; Male; Phorbol Esters; Prostatic Neoplasms; Protein Kinase C; Protein Kinase C-delta; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha | 2010 |
Protein kinase C inhibitors alter neurotensin receptor binding and function in prostate cancer PC3 cells.
Topics: Binding Sites; Cell Line, Tumor; Down-Regulation; Humans; Inhibitory Concentration 50; Inositol Phosphates; Male; Phorbol Esters; Phosphorylation; Prostatic Neoplasms; Protein Kinase C; Protein Kinase Inhibitors; Receptors, Neurotensin | 2008 |